Calpain-2 inhibition alleviates hypercalcemia-driven multiple myeloma progression
Biochemical Pharmacology · 2026-09 · 251 · 118174
DOI: 10.1016/j.bcp.2026.118174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-09. Verfasst von Zeyuan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Xiangya Hospital, Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Centra…. Hauptthemen laut MEDLINE: Calpain, Multiple Myeloma, Hypercalcemia, Disease Progression. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Hunan Provincial Natural Science Foundation, Fundamental Research Funds for Central Universities of the Central South University.
Abstract (Originalsprache)
Multiple myeloma (MM) is a malignant hematological disorder characterized by the neoplastic proliferation of plasma cells. Hypercalcemia is a common complication in MM and is often considered a secondary consequence of disease progression. When calcium levels are severely elevated, it can lead to coma in affected patients. However, whether hypercalcemia plays a direct role in MM progression remains unclear. Herein we found that high calcium concentrations promote MM cell proliferation and it was associated with calpain-2 (CAPN2). We also observed that CAPN2 expression is significantly increased in MM patients and correlates with poor prognosis. Furthermore, knockdown of CAPN2 inhibited MM cell proliferation both in vitro and in vivo via upregulation of FN14 and induction of apoptosis. Importantly, treatment with ALLN, a CAPN2 inhibitor, substantially suppressed MM cell proliferation in vitro and in vivo by inducing apoptosis. Notably, ALLN significantly enhanced the sensitivity of MM cells to commonly used clinical drugs bortezomib and doxorubicin, while exhibiting no obvious cytotoxicity in normal cells. These findings establish CAPN2 as a promising therapeutic target in MM, with its inhibitor serving as a potential lead compound for further clinical evaluation. Our study also elucidates the relationship between hypercalcemia, CAPN2, and malignant proliferation in MM cells, and expands the therapeutic landscape for MM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Second Xiangya Hospital, Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha 410013, Hunan, China.
- Department of Clinical Laboratory, The Affiliated Nanhua Hospital, University of South China, Hengyang 421001, Hunan, China.
- Department of Histology and Embryology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, Hunan, China.
- Department of Hematology, The Second Xiangya Hospital, Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha 410013, Hunan, China. Electronic address:…
- Department of Lymphoma and Hematology, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China. Electronic address: zhouhui@hnca.org.cn.
Förderung
- Hunan Provincial Natural Science Foundation
- Fundamental Research Funds for Central Universities of the Central South University
Zitieren
APA
Wang, Z., Yang, C., Wang, Y., Guo, Z., Jin, R., Xiao, L., Liu, J., Zhou, H., Xiao, X., & Han, X. (2026). Calpain-2 inhibition alleviates hypercalcemia-driven multiple myeloma progression. Biochemical Pharmacology, 251, 118174. https://doi.org/10.1016/j.bcp.2026.118174
Vancouver
Wang Z, Yang C, Wang Y, Guo Z, Jin R, Xiao L, et al. Calpain-2 inhibition alleviates hypercalcemia-driven multiple myeloma progression. Biochemical Pharmacology. 2026;251:118174. doi:10.1016/j.bcp.2026.118174
BibTeX
@article{Wang2026,
author = {Wang, Zeyuan and Yang, Chaoying and Wang, Yanpeng and Guo, Zhiming and Jin, Ruibo and Xiao, Ling and Liu, Jing and Zhou, Hui and Xiao, Xiaojuan and Han, Xu},
title = {Calpain-2 inhibition alleviates hypercalcemia-driven multiple myeloma progression},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {251},
pages = {118174},
doi = {10.1016/j.bcp.2026.118174}
}
EUVIMED